The Safety and Tolerability of 5-Aminolevulinic Acid Phosphate with Sodium Ferrous Citrate in Patients with Type 2 Diabetes Mellitus in Bahrain

Table 2

Summary of adverse events.

	5-ALA-SFC	Placebo
Subjects reporting at least one event	16 (45.7%)	5 (27.8%)
Subjects reporting at least one related event	7 (20%)	3 (16.7%)
Subjects reporting at least one severe event	0	0
Subjects reporting at least one event leading to study discontinuation	6 (17.1%)	1 (5.6%)

= 0.206.